{"id":10260,"date":"2026-07-15T11:42:23","date_gmt":"2026-07-15T09:42:23","guid":{"rendered":"https:\/\/cleanpeptides.eu\/tesamorelina-guia-dosagem\/"},"modified":"2026-07-15T11:42:23","modified_gmt":"2026-07-15T09:42:23","slug":"tesamorelina-guia-dosagem","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/pt-pt\/tesamorelina-guia-dosagem\/","title":{"rendered":"Guia de dosagem Tesamorelina"},"content":{"rendered":"<p><em>Apenas para fins de investiga\u00e7\u00e3o \u2014 n\u00e3o destinado ao uso humano. A Clean Peptides n\u00e3o fornece aconselhamento sobre dosagem ou utiliza\u00e7\u00e3o. Este guia re\u00fane informa\u00e7\u00e3o do produto e material educativo independente como refer\u00eancia de investiga\u00e7\u00e3o; n\u00e3o constitui aconselhamento m\u00e9dico.<\/em><\/p>\n<h2>O que \u00e9 a Tesamorelina?<\/h2>\n<p>A Tesamorelina (nome comercial Egrifta) \u00e9 um an\u00e1logo sint\u00e9tico da GHRH \u2014 os 44 amino\u00e1cidos completos da GHRH humana (1-44) com uma modifica\u00e7\u00e3o N-terminal de \u00e1cido trans-3-hexen\u00f3ico para estabilidade. Recebeu aprova\u00e7\u00e3o da FDA em 2010 para reduzir o excesso de gordura abdominal (lipodistrofia) em doentes infetados com VIH. Ao contr\u00e1rio da HGH ex\u00f3gena, estimula uma liberta\u00e7\u00e3o puls\u00e1til de GH preservando o ciclo de retroalimenta\u00e7\u00e3o da somatostatina, reduzindo o risco de GH\/IGF-1 suprafisiol\u00f3gico. Os ensaios mostraram uma redu\u00e7\u00e3o de 15 a 18 % do tecido adiposo visceral em 26 semanas.<\/p>\n<h2>Caracter\u00edsticas principais<\/h2>\n<ul>\n<li>An\u00e1logo da GHRH (44 amino\u00e1cidos) \u2014 o \u00fanico an\u00e1logo da GHRH aprovado pela FDA.<\/li>\n<li>Aprovado pela FDA (2010) \u2014 para a lipodistrofia associada ao VIH (Egrifta \/ Egrifta SV).<\/li>\n<li>Liberta\u00e7\u00e3o puls\u00e1til de GH \u2014 preserva o ciclo de retroalimenta\u00e7\u00e3o da somatostatina.<\/li>\n<li>Especificidade para a gordura visceral \u2014 redu\u00e7\u00e3o de 15\u201318 % do VAT em 26 semanas; efeito m\u00ednimo na gordura subcut\u00e2nea.<\/li>\n<li>Potencial cognitivo \u2014 o estudo STAY (2019) mostrou cogni\u00e7\u00e3o preservada em idosos seropositivos.<\/li>\n<\/ul>\n<h2>Como se determina a dose<\/h2>\n<p>Excecionalmente bem estabelecida \u2014 processo completo de aprova\u00e7\u00e3o da FDA. A dose de 2 mg di\u00e1rios foi selecionada na fase II e confirmada em ECA de fase III (800 doentes, Falutz et al. 2007, 2010). Redu\u00e7\u00e3o do VAT de 15\u201318 % vs placebo \u00e0s 26 semanas. Estudo STAY: ECA cognitivo de 12 meses. N\u00edvel de evid\u00eancia: forte.<\/p>\n<h2>Dosagem padr\u00e3o<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protocolo<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Dose<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Frequ\u00eancia<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Notas<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Aprovado FDA (Egrifta)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uma vez\/dia<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Dose dos ensaios de fase III, endpoint \u00e0s 26 semanas<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Padr\u00e3o off-label<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uma vez\/dia<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Composi\u00e7\u00e3o corporal \/ antienvelhecimento, inje\u00e7\u00e3o \u00e0 noite<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Conservador<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">1 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Uma vez\/dia<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Menos dados cl\u00ednicos nesta dose<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 on \/ 2 off (comunidade)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">2 mg SC<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">5 dias\/semana<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Prolonga o uso do frasco, n\u00e3o estudado em ensaios<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<h2>Reconstitui\u00e7\u00e3o e dosagem (com os 3 mL fornecidos)<\/h2>\n<p>Cada frasco da Clean Peptides vem com 3 mL de \u00e1gua bacteriost\u00e1tica (\u00e1lcool benz\u00edlico 0,9 %). Todos os valores abaixo pressup\u00f5em a reconstitui\u00e7\u00e3o com os 3 mL completos. Numa seringa de insulina U-100 padr\u00e3o, 100 unidades = 1 mL.<\/p>\n<p><strong>F\u00f3rmula r\u00e1pida:<\/strong> concentra\u00e7\u00e3o = pot\u00eancia do frasco \u00f7 3 mL; unidades a extrair = dose (mg) \u00d7 300 \u00f7 pot\u00eancia do frasco (mg).<\/p>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Frasco (Clean Peptides)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Concentra\u00e7\u00e3o<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">1 mg<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">2 mg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">10 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">3,33 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">30 u<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">60 u<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>Guarde o produto reconstitu\u00eddo no frigor\u00edfico (2\u20138 \u00b0C) e utilize-o dentro de 28 a 30 dias.<\/p>\n<h2>Dosagem por objetivo<\/h2>\n<ul>\n<li><strong>Redu\u00e7\u00e3o de gordura visceral (indica\u00e7\u00e3o FDA):<\/strong> 2 mg SC\/dia, 26 semanas no m\u00ednimo. TC\/DEXA no in\u00edcio e \u00e0s 26 sem.; IGF-1 no in\u00edcio, 8 sem., 26 sem. \u00c0 noite\/ao deitar, em jejum 1\u20132 h.<\/li>\n<li><strong>Composi\u00e7\u00e3o corporal e antienvelhecimento (off-label):<\/strong> 2 mg SC\/dia, \u00e0 noite\/ao deitar, em jejum, 12\u201326 semanas e depois pausa.<\/li>\n<li><strong>Apoio cognitivo:<\/strong> 2 mg SC\/dia, 12 meses (estudo STAY); dados limitados \u00e0 popula\u00e7\u00e3o seropositiva.<\/li>\n<\/ul>\n<h2>Guia de inje\u00e7\u00e3o<\/h2>\n<p>Lave as m\u00e3os e prepare uma superf\u00edcie limpa. Desinfete a tampa do frasco e deixe secar. Extraia a dose (normalmente o frasco inteiro para 2 mg) e expulse as bolhas. Escolha o abd\u00f3men (local aprovado pela FDA), a 2\u20133 cm do umbigo, evitando tecido cicatricial. Limpe o local e deixe secar. Injete numa prega beliscada a 45\u00b0. Elimine num contentor de agulhas. Momento \u00f3timo: \u00e0 noite\/ao deitar (sinergia com o pico noturno de GH), em jejum 1\u20132 h. Dose di\u00e1ria constante, alternando dentro do abd\u00f3men.<\/p>\n<h2>Dura\u00e7\u00e3o e momento do ciclo<\/h2>\n<figure class=\"wp-block-table\">\n<table style=\"border-collapse:collapse;width:100%\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Protocolo<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Dura\u00e7\u00e3o<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;background:#f4f4f4;text-align:left\">Notas<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Padr\u00e3o (ensaio FDA)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">26 semanas di\u00e1rio<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Endpoint principal de fase III<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">Alargado<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">52 semanas di\u00e1rio<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Benef\u00edcio mantido, maior dura\u00e7\u00e3o estudada<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">C\u00edclico<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">26 sem. on, 8\u201312 sem. off, repetir<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Recupera\u00e7\u00e3o hipofis\u00e1ria, gest\u00e3o do custo<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px\">5 on \/ 2 off semanal<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Cont\u00ednuo, 5 dias\/semana<\/td>\n<td style=\"border:1px solid #ddd;padding:8px\">Reduz o custo em 30 %, n\u00e3o estudado<\/td>\n<\/tr>\n<\/table>\n<\/figure>\n<p>A gordura visceral volta a acumular-se ap\u00f3s a interrup\u00e7\u00e3o; o IGF-1 normaliza em poucas semanas. N\u00e3o requer PCT (a hip\u00f3fise n\u00e3o fica suprimida).<\/p>\n<h2>Combina\u00e7\u00f5es (stacking)<\/h2>\n<p><strong>Tesamorelina + Ipamorelina<\/strong> \u2014 sinergia GHRH + GHRP (refer\u00eancia): Tesamorelina 2 mg SC \u00e0 noite + Ipamorelina 200\u2013300 mcg SC ao deitar, em jejum. Vias de recetor distintas \u2192 resposta GH sin\u00e9rgica. Outras combina\u00e7\u00f5es: + AOD-9604 (lip\u00f3lise direta, de manh\u00e3 em jejum) ou + BPC-157 (otimiza\u00e7\u00e3o de GH + repara\u00e7\u00e3o de tecidos).<\/p>\n<h2>Seguran\u00e7a, efeitos secund\u00e1rios e contraindica\u00e7\u00f5es<\/h2>\n<p><strong>Rastreio de cancro obrigat\u00f3rio<\/strong> \u2014 a GH\/IGF-1 promove o crescimento celular; um tumor ativo \u00e9 uma contraindica\u00e7\u00e3o na bula FDA. Fa\u00e7a um rastreio adequado \u00e0 idade antes de come\u00e7ar.<\/p>\n<p>Frequentes (fase III): rea\u00e7\u00f5es no local da inje\u00e7\u00e3o (13 %), artralgia (13 %), edema perif\u00e9rico, mialgia. Menos frequentes: hiperglicemia\/resist\u00eancia \u00e0 insulina, s\u00edndrome do t\u00fanel c\u00e1rpico, parestesia, n\u00e1usea.<\/p>\n<p><strong>Contraindica\u00e7\u00f5es:<\/strong> tumor ativo; eixo hipot\u00e1lamo-hipofis\u00e1rio alterado; gravidez (categoria X); hipersensibilidade (incluindo manitol); diabetes n\u00e3o controlada.<\/p>\n<p><strong>Monitoriza\u00e7\u00e3o:<\/strong> IGF-1 (in\u00edcio, 8 sem., 26 sem.), glicose em jejum e HbA1c, rastreio de cancro, perfil tiroideu, l\u00edpidos. N\u00e3o combinar com HGH ex\u00f3gena. Medicamento sujeito a receita; proibido pela AMA (WADA).<\/p>\n<h2>Erros frequentes<\/h2>\n<ul>\n<li>Injetar ap\u00f3s uma refei\u00e7\u00e3o em vez de em jejum.<\/li>\n<li>Esperar resultados de n\u00edvel HGH de um an\u00e1logo da GHRH.<\/li>\n<li>Parar antes das 26 semanas.<\/li>\n<li>Ignorar a monitoriza\u00e7\u00e3o do IGF-1.<\/li>\n<li>Combinar com HGH ex\u00f3gena.<\/li>\n<li>Come\u00e7ar sem rastreio de cancro.<\/li>\n<li>Dosagem di\u00e1ria inconstante.<\/li>\n<li>Usar Egrifta (\u00e1gua est\u00e9ril) al\u00e9m de 24 horas.<\/li>\n<\/ul>\n<h2>Pontos-chave<\/h2>\n<ul>\n<li>O \u00fanico an\u00e1logo da GHRH aprovado pela FDA; a evid\u00eancia cl\u00ednica mais forte de qualquer p\u00e9ptido de GH.<\/li>\n<li>Dose fixa de 2 mg SC uma vez por dia (sem ajuste ao peso).<\/li>\n<li>Liberta\u00e7\u00e3o puls\u00e1til de GH preservando a retroalimenta\u00e7\u00e3o; redu\u00e7\u00e3o de 15\u201318 % de gordura visceral em 26 semanas.<\/li>\n<li>Injetar ao deitar, em jejum. Melhor stack: Tesamorelina + Ipamorelina.<\/li>\n<li>Rastreio de cancro obrigat\u00f3rio; monitorizar o IGF-1; n\u00e3o combinar com HGH.<\/li>\n<\/ul>\n<h2>Descarga e recursos relacionados<\/h2>\n<p><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/11-Tesamorelin-Dosage-Guide-Clean-Peptides.pdf\">\ud83d\udcc4 Descarregar o guia PDF completo<\/a><\/p>\n<p><a href=\"https:\/\/cleanpeptides.eu\/product\/tesamorelin-10-mg\/\">Tesamorelina 10 mg<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/ipamorelin-dosage-guide\/\">Guia de dosagem Ipamorelina<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/mots-c-dosage-guide\/\">Guia de dosagem MOTS-c<\/a><\/p>\n<h2>Refer\u00eancias<\/h2>\n<ol>\n<li>Falutz J, et al. \u00abTesamorelin on visceral fat reduction in HIV-infected patients.\u00bb N Engl J Med. 2007;357:2359-2370.<\/li>\n<li>Falutz J, et al. \u00abMetabolic effects of a GH-releasing factor in patients with HIV.\u00bb J Clin Endocrinol Metab. 2010;95(9):4291-4304.<\/li>\n<li>Stanley TL, et al. \u00abTesamorelin on visceral and liver fat in HIV patients.\u00bb JAMA. 2014;312(4):380-389.<\/li>\n<li>Stanley TL, et al. \u00abTesamorelin effects on neuropsychological function in HIV older adults.\u00bb AIDS. 2019;33(7):1179-1188.<\/li>\n<li>Dhillon S. \u00abTesamorelin: a review in HIV-associated lipodystrophy.\u00bb Drugs. 2011;71(8):1071-1091.<\/li>\n<\/ol>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>Apenas para fins de investiga\u00e7\u00e3o \u2014 n\u00e3o destinado ao uso humano. A Clean Peptides n\u00e3o fornece aconselhamento sobre dosagem ou [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10260","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages\/10260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/comments?post=10260"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/pages\/10260\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/pt-pt\/wp-json\/wp\/v2\/media?parent=10260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}